← All candidates
85 insider filings on record.
85 filings on record.
RPRXRoyalty Pharma plc
NasdaqGS · Healthcare · $33.73B
$59.05
+0.75% · Sep 14
85 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 55 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$33.73B
Float
415.5M
93% public
Short % float
Pro
Price / profit
31.4
Price / future profit
10.2
Price / sales
13.3
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
80 more transactions on Pro →Context
Wall St
$61.63 avg target
+4.4% vs today · 8 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q2 '26$1.32 act+$0.05
Q1 '26$1.30 act+$0.11
Q4 '25$1.47 act+$0.13
Q3 '25$1.17 act+$0.13
Coverage
Royalty Pharma Q2 Earnings Call HighlightsMarketBeat · 08-05Royalty Pharma PLC (RPRX) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised GuidanceGuruFocus.com · 08-05Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks · 08-05Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue EstimatesZacks · 08-05
The file stays open
85 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice